| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2,062.9 | 2,001.4 |
| Profit before tax | 230.1 | 279.2 |
| Net income | 191.6 | 230.9 |
| EPS (diluted, $ a share) | $1.00 | $1.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -17.0% |
|---|---|
| Revenue, year on year | +3.1% |
| Operating margin | 14.9% |
10-Q filed with the SEC, NYSE: ZBH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zimmer Biomet Holdings, Inc.: key numbers
- Share price
- $101.41Close, Nov 16
- Market cap
- $19.2B
- Shares outstanding
- 189.25MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zimmer Biomet Holdings, Inc.
All →Zimmer Biomet Holdings $500M Debt Financing with Barclays Capital Inc.
Zimmer Biomet Holdings, Inc. completed a dual-currency public offering of senior notes, consisting of $500 million of 5.850% notes due 2036 and €500 million of 4.375% notes due 2033. The proceeds are intended to be used for general corporate purposes, which may include the repayment of existing 2.425% notes due 2026 and 4.700% notes due 2027.
- Value
- $500M
- Counterparty
- Barclays Capital Inc.
- Term
- through 2036
Zimmer Biomet Holdings Financial Results
Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, a 3.1% increase over the prior year, driven by strong performance in its Hips, S.E.T., and Technology & Data franchises. The company updated its full-year 2026 guidance, raising its organic constant-currency sales growth and adjusted EPS targets based on solid commercial execution.
- Term
- Q3 2026
“We are very pleased with our solid third quarter results, growing net sales 3.7% on a constant-currency basis and generating strong operating and free cash flow. Our Hips, S.E.T. and Technology & Data, Bone Cement and Surgical franchises – representing two-thirds of our book of business – grew at upper single digit or double-digit rates, validating the progress of our diversification strategy, the strength of our innovation engine and the significant strides we are making in commercial execution.”
Ivan Tornos, Chairman, President and CEO of Zimmer Biomet